CA2486302A1 - Methodes de prevention et/ou de traitement de troubles neurologiques - Google Patents

Methodes de prevention et/ou de traitement de troubles neurologiques Download PDF

Info

Publication number
CA2486302A1
CA2486302A1 CA002486302A CA2486302A CA2486302A1 CA 2486302 A1 CA2486302 A1 CA 2486302A1 CA 002486302 A CA002486302 A CA 002486302A CA 2486302 A CA2486302 A CA 2486302A CA 2486302 A1 CA2486302 A1 CA 2486302A1
Authority
CA
Canada
Prior art keywords
udp
glucuronosyltransferase
glutamate
ugt
substrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002486302A
Other languages
English (en)
Inventor
Pascal Neuville
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Domain Therapeutics SA
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2486302A1 publication Critical patent/CA2486302A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Addiction (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne l'utilisation de substrats d'une UDP-glucuronosyltransférase (UGT) et de sels de ceux-ci pour la prévention et/ou le traitement de troubles neurologiques. Dans un mode de réalisation préféré, l'invention concerne l'utilisation de substrats d'au moins une UDP-glucuronosyltransférase (UGT) exprimée dans le cerveau et de sels de ceux-ci, pour la prévention et/ou le traitement de troubles neurologiques. L'invention concerne également l'utilisation de ces substrats et de sels de ceux-ci pour prévenir et/ou traiter la cytotoxicité due au glutamate, et plus spécifiquement des troubles neurologiques induits par le glutamate. En outre, l'invention concerne l'utilisation de ces substrats et de sels de ceux-ci pour fabriquer des médicaments exerçant un effet d'inhibition sur la libération de glutamate.
CA002486302A 2002-05-17 2003-05-16 Methodes de prevention et/ou de traitement de troubles neurologiques Abandoned CA2486302A1 (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP02291218.2 2002-05-17
EP02291218 2002-05-17
EP02291600 2002-06-27
EP02291600.1 2002-06-27
US39310802P 2002-07-03 2002-07-03
US60/393,108 2002-07-03
PCT/EP2003/005186 WO2003097024A1 (fr) 2002-05-17 2003-05-16 Methodes de prevention et/ou de traitement de troubles neurologiques

Publications (1)

Publication Number Publication Date
CA2486302A1 true CA2486302A1 (fr) 2003-11-27

Family

ID=29553807

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002486302A Abandoned CA2486302A1 (fr) 2002-05-17 2003-05-16 Methodes de prevention et/ou de traitement de troubles neurologiques

Country Status (4)

Country Link
JP (1) JP2005530778A (fr)
AU (1) AU2003236668A1 (fr)
CA (1) CA2486302A1 (fr)
WO (1) WO2003097024A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006066361A1 (fr) 2004-12-24 2006-06-29 The University Of Queensland Procede de traitement ou prophylaxie
US20130131007A1 (en) 2005-09-07 2013-05-23 Bebaas, Inc. Vitamin b12 compositions
WO2007035029A1 (fr) * 2005-09-23 2007-03-29 Sk Holdings Co., Ltd. Composition pharmaceutique pour la prevention et le traitement de la toxicomanie ou de l'alcoolisme ou de trouble bipolaire mettant en oeuvre du phenylbutyrate de sodium
CA2866540A1 (fr) 2006-03-20 2007-09-27 Spinifex Pharmaceuticals Pty Ltd. Methode de traitement prophylactique ou therapeutique
JP2016530265A (ja) * 2013-08-12 2016-09-29 ベナロヤ リサーチ インスティテュート アット バージニア メイソン 免疫調節のための４−メチルウンベリフェロン処置
KR101726513B1 (ko) * 2015-09-21 2017-04-13 경북대학교 산학협력단 실리비닌을 유효성분으로 포함하는 뇌전증의 예방 또는 치료용 조성물

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI962356A1 (it) * 1996-11-13 1998-05-13 Uni Degli Studi Di Brescia D I Uso di composti derivati da molecole ad attivita' antinfiammatoria di tipo non steroideo per la prevenzione e il trattamento di

Also Published As

Publication number Publication date
AU2003236668A1 (en) 2003-12-02
WO2003097024A1 (fr) 2003-11-27
JP2005530778A (ja) 2005-10-13

Similar Documents

Publication Publication Date Title
Culp et al. Ketamine use for cancer and chronic pain management
Hong et al. Potential therapeutic effects and pharmacological evidence of sinomenine in central nervous system disorders
Herman et al. The effects of NMDA receptor antagonists and nitric oxide synthase inhibitors on opioid tolerance and withdrawal
Wolkerstorfer et al. New approaches to treating pain
KR101663998B1 (ko) 샤르코-마리-투스 질환 및 관련 장애를 치료하기 위한 필로카핀 및 메티마졸 조합
RU2726131C2 (ru) Внеклеточная днк в качестве терапевтической мишени при нейродегенерации
EA024147B1 (ru) Комбинированные композиции для лечения болезни альцгеймера и родственных заболеваний зонизамидом и акампросатом
RU2760558C9 (ru) Целевой лекарственный препарат и новые композиции, комбинации на его основе и способы их применения
Lu et al. NGF‐Dependent activation of TrkA pathway: A mechanism for the neuroprotective effect of troxerutin in D‐galactose‐treated mice
Shao et al. Pinocembrin promotes OPC differentiation and remyelination via the mTOR signaling pathway
US20040014648A1 (en) Methods for the prevention and/or the treatment of neurological disorders
WO2006037069A1 (fr) Compositions comprenant nb-dnj, ne-dnj ou d-glucaro-delta-lactame et leurs utilisations pour le traitement de la douleur et autres etats neurologiques
CA2486302A1 (fr) Methodes de prevention et/ou de traitement de troubles neurologiques
US20080194669A1 (en) T Type Calcium Channel Blockers and the Treatment of Diseases
US10842807B2 (en) Methods of treating neurodegenerative disorders comprising DNA methyltransferase inhibitors
PT100756B (pt) Novos derivados de gangliosidos, processo para a sua preparacao e composicoes farmaceuticas que os contem
EP1371366A1 (fr) Méthode de prévention et de traitement de troubles neurologiques
US20070093433A1 (en) Aminoglycoside antibiotics for use as vap-1/ssao inhibitors
Monica et al. GENETIC VARIABILITY OF PHARMACOKINETICS AND PHARMACODYNAMICS OF ANALGESICS (LAYERED MEDICINE)
Ezell et al. Mechanisms of action of clinically relevant analgesics (non-opiates)
NEAMŢU et al. GENETIC VARIABILITY OF PHARMACOKINETICS AND PHARMACODYNAMICS OF ANALGESICS (LAYERED MEDICINE)-PART II
CN1481801A (zh) 四环素类药防治帕金森及一氧化氮有关的神经退行性疾病
Du et al. AI Med
Li Neuroprotective Effects of Monoterpene Indole Alkaloids from Ervatamia officinalis in Experimental Models of Neuroinflammation
EP1855665B1 (fr) Utilisation de derives de phenylacetyle pour la production d'un medicament employe dans le traitement de la maladie de von hippel-lindau (vhl)

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued